Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals, Inc. (IONS) is a healthcare company (biotechnology) based in the United States. The share price is $27.01, down 3.58% on the day, which values the company at $4.5B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.
Key facts
- Share price
- $27.01−3.58% today
- Market value
- $4.5B
- Funk Score
- 34/100
- Against its own history
- Well below its usual priceusual price $40.90
- 200-week average
- $48.9345% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Ionis Pharmaceuticals, Inc. in more detail
IONS trades at -13.3× next year's expected earnings, 4.7× sales. Measured against its own history, the price is 34% below what its usual multiples would imply ($40.90) — well below its usual price. It sits 45% below its 200-week average of $48.93.
Over the last five fiscal years Ionis Pharmaceuticals, Inc. has compounded revenue 5.3% a year. Its Funk Score is 34 out of 100 (financial strength 3.6, profitability 0.8, growth 6.1, value 3.1, each out of 10).
In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.
4 of the superinvestors tracked here hold IONS, including Tweedy, Browne team (6.5% of the portfolio), Julian and Felix Baker (0.8% of the portfolio), Cathie Wood (0.2% of the portfolio).
Superinvestors holding IONS
4 of the investors tracked here report a position in their latest 13F filing.
- Tweedy, Browne team Tweedy, Browne Company6.52% of portfolio · $80.1M · trimmed · Q3 2026
- Julian and Felix Baker Baker Bros. Advisors0.81% of portfolio · $162.4M · Q2 2026
- Cathie Wood ARK Invest0.24% of portfolio · $41.2M · added · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.22% of portfolio · $300.4M · added · Q3 2026
Health Care companies of similar size
- ErascaERAS
- Concentra Group Holdings ParentCON
- Merit Medical SystemsMMSI
- Edgewise TherapeuticsEWTX
- LivaNovaLIVN
- Dianthus TherapeuticsDNTH
- MiniMed GroupMMED
- Adaptive BiotechnologiesADPT
- HeartflowHTFL
- CRISPR TherapeuticsCRSP
- Travere TherapeuticsTVTX
- Option Care HealthOPCH
Side by side:IONS vs LIVN (Ionis Pharmaceuticals, Inc. vs LivaNova)IONS vs DNTH (Ionis Pharmaceuticals, Inc. vs Dianthus Therapeutics)IONS vs MMED (Ionis Pharmaceuticals, Inc. vs MiniMed Group)IONS vs ADPT (Ionis Pharmaceuticals, Inc. vs Adaptive Biotechnologies)IONS vs EWTX (Ionis Pharmaceuticals, Inc. vs Edgewise Therapeutics)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Ionis Pharmaceuticals, Inc. (IONS): questions and answers
What is IONS's PEG ratio?
Ionis Pharmaceuticals, Inc.'s PEG ratio is 27.33 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Ionis Pharmaceuticals, Inc.'s market cap?
Ionis Pharmaceuticals, Inc. is valued at $4.5B at a share price of $27.01.
Is IONS overvalued or undervalued?
Against its own history, IONS is well below its usual price: the price is 34% below the $40.90 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is IONS above its 200-week moving average?
No. IONS is 44.8% below its 200-week average of $48.93. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Ionis Pharmaceuticals, Inc. growing?
Over the last five fiscal years Ionis Pharmaceuticals, Inc.'s revenue grew 5.3% a year; over ten years revenue grew 12.8% a year.
Does IONS pay a dividend?
Ionis Pharmaceuticals, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Ionis Pharmaceuticals, Inc. (IONS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IONS
Underlying data: Yahoo Finance; company filings with the SEC.